Loading...
Header Logo
Keywords
Last Name
Institution

Dr Neeloo Singh

Title[no position]
Institution[no institution name]
Address[no address]
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Singh N, Sundar S. Integrating genomics and proteomics permits identification of immunodominant antigens associated with drug resistance in human visceral leishmaniasis in India. Exp Parasitol. 2017 May; 176:30-45. PMID: 28263760.
      View in: PubMed
    2. Chauhan IS, Shukla R, Krishna S, Sekhri S, Kaushik U, Baby S, Pal C, Siddiqi MI, Sundar S, Singh N. Recombinant Leishmania Rab6 (rLdRab6) is recognized by sera from visceral leishmaniasis patients. Exp Parasitol. 2016 Nov; 170:135-147. PMID: 27666959.
      View in: PubMed
    3. Chauhan IS, Kaur J, Krishna S, Ghosh A, Singh P, Siddiqi MI, Singh N. Evolutionary comparison of prenylation pathway in kinetoplastid Leishmania and its sister Leptomonas. BMC Evol Biol. 2015 Nov 21; 15:261. PMID: 26588894.
      View in: PubMed
    4. Zahir AA, Chauhan IS, Bagavan A, Kamaraj C, Elango G, Shankar J, Arjaria N, Roopan SM, Rahuman AA, Singh N. Green Synthesis of Silver and Titanium Dioxide Nanoparticles Using Euphorbia prostrata Extract Shows Shift from Apoptosis to G0/G1 Arrest followed by Necrotic Cell Death in Leishmania donovani. Antimicrob Agents Chemother. 2015 Aug; 59(8):4782-99. PMID: 26033724.
      View in: PubMed
    5. Singh N, Chatterjee M, Sundar S. The overexpression of genes of thiol metabolism contribute to drug resistance in clinical isolates of visceral leishmaniasis (kala azar) in India. Parasit Vectors. 2014 Dec 17; 7:596. PMID: 25515494.
      View in: PubMed
    6. Wilson N, Driss A, Solomon W, Dickinson-Copeland C, Salifu H, Jain V, Singh N, Stiles J. CXCL10 gene promoter polymorphism -1447A>G correlates with plasma CXCL10 levels and is associated with male susceptibility to cerebral malaria. PLoS One. 2013; 8(12):e81329. PMID: 24349056.
      View in: PubMed
    7. Singh N, Chikara S, Sundar S. SOLiD™ sequencing of genomes of clinical isolates of Leishmania donovani from India confirm leptomonas co-infection and raise some key questions. PLoS One. 2013; 8(2):e55738. PMID: 23418454.
      View in: PubMed
    8. Kaur J, Dutta S, Chang KP, Singh N. A member of the Ras oncogene family, RAP1A, mediates antileishmanial activity of monastrol. J Antimicrob Chemother. 2013 May; 68(5):1071-80. PMID: 23292345.
      View in: PubMed
    9. Kaur J, Tiwari R, Kumar A, Singh N. Bioinformatic Analysis of Leishmania donovani Long-Chain Fatty Acid-CoA Ligase as a Novel Drug Target. Mol Biol Int. 2011; 2011:278051. PMID: 22091399.
      View in: PubMed
    10. Lucchi NW, Jain V, Wilson NO, Singh N, Udhayakumar V, Stiles JK. Potential serological biomarkers of cerebral malaria. Dis Markers. 2011; 31(6):327-35. PMID: 22182805.
      View in: PubMed
    11. Wilson NO, Jain V, Roberts CE, Lucchi N, Joel PK, Singh MP, Nagpal AC, Dash AP, Udhayakumar V, Singh N, Stiles JK. CXCL4 and CXCL10 predict risk of fatal cerebral malaria. Dis Markers. 2011; 30(1):39-49. PMID: 21508508.
      View in: PubMed
    12. Kaur J, Kumar P, Tyagi S, Pathak R, Batra S, Singh P, Singh N. In silico screening, structure-activity relationship, and biologic evaluation of selective pteridine reductase inhibitors targeting visceral leishmaniasis. Antimicrob Agents Chemother. 2011 Feb; 55(2):659-66. PMID: 21115787.
      View in: PubMed
    13. Kaur J, Sundar S, Singh N. Molecular docking, structure-activity relationship and biological evaluation of the anticancer drug monastrol as a pteridine reductase inhibitor in a clinical isolate of Leishmania donovani. J Antimicrob Chemother. 2010 Aug; 65(8):1742-8. PMID: 20519355.
      View in: PubMed
    14. Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, Chatterjee M. Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol. 2010 Oct; 173(2):162-4. PMID: 20553768.
      View in: PubMed
    15. Kaur J, Singh N, Singh BK, Dube A, Tripathi RP, Singh P, Singh N. Leishmania donovani: oral therapy with glycosyl 1,4-dihydropyridine analogue showing apoptosis like phenotypes targeting pteridine reductase 1 in intracellular amastigotes. Exp Parasitol. 2010 Jul; 125(3):310-4. PMID: 20219462.
      View in: PubMed
    16. Kaur J, Singh BK, Tripathi RP, Singh P, Singh N. Leishmania donovani: a glycosyl dihydropyridine analogue induces apoptosis like cell death via targeting pteridine reductase 1 in promastigotes. Exp Parasitol. 2009 Nov; 123(3):258-64. PMID: 19647734.
      View in: PubMed
    17. Singh N, Kaur J, Kumar P, Gupta S, Singh N, Ghosal A, Dutta A, Kumar A, Tripathi R, Siddiqi MI, Mandal C, Dube A. An orally effective dihydropyrimidone (DHPM) analogue induces apoptosis-like cell death in clinical isolates of Leishmania donovani overexpressing pteridine reductase 1. Parasitol Res. 2009 Oct; 105(5):1317-25. PMID: 19621245.
      View in: PubMed
    18. Sarkar A, Mandal G, Singh N, Sundar S, Chatterjee M. Flow cytometric determination of intracellular non-protein thiols in Leishmania promastigotes using 5-chloromethyl fluorescein diacetate. Exp Parasitol. 2009 Aug; 122(4):299-305. PMID: 19393240.
      View in: PubMed
    19. Mandal G, Sarkar A, Saha P, Singh N, Sundar S, Chatterjee M. Functionality of drug efflux pumps in antimonial resistant Leishmania donovani field isolates. Indian J Biochem Biophys. 2009 Feb; 46(1):86-92. PMID: 19374259.
      View in: PubMed
    20. Kumari S, Kumar A, Samant M, Singh N, Dube A. Discovery of novel vaccine candidates and drug targets against visceral leishmaniasis using proteomics and transcriptomics. Curr Drug Targets. 2008 Nov; 9(11):938-47. PMID: 18991606.
      View in: PubMed
    21. Kumar P, Kumar A, Verma SS, Dwivedi N, Singh N, Siddiqi MI, Tripathi RP, Dube A, Singh N. Leishmania donovani pteridine reductase 1: biochemical properties and structure-modeling studies. Exp Parasitol. 2008 Sep; 120(1):73-9. PMID: 18617167.
      View in: PubMed
    22. Kumari S, Kumar A, Samant M, Sundar S, Singh N, Dube A. Proteomic approaches for discovery of new targets for vaccine and therapeutics against visceral leishmaniasis. Proteomics Clin Appl. 2008 Mar; 2(3):372-86. PMID: 21136840.
      View in: PubMed
    23. Singh N, Almeida R, Kothari H, Kumar P, Mandal G, Chatterjee M, Venkatachalam S, Govind MK, Mandal SK, Sundar S. Differential gene expression analysis in antimony-unresponsive Indian kala azar (visceral leishmaniasis) clinical isolates by DNA microarray. Parasitology. 2007 Jun; 134(Pt 6):777-87. PMID: 17306059.
      View in: PubMed
    24. Kumar P, Sundar S, Singh N. Degradation of pteridine reductase 1 (PTR1) enzyme during growth phase in the protozoan parasite Leishmania donovani. Exp Parasitol. 2007 Jun; 116(2):182-9. PMID: 17275814.
      View in: PubMed
    25. Kothari H, Kumar P, Sundar S, Singh N. Possibility of membrane modification as a mechanism of antimony resistance in Leishmania donovani. Parasitol Int. 2007 Mar; 56(1):77-80. PMID: 17169604.
      View in: PubMed
    26. Kothari H, Kumar P, Saluja R, Sundar S, Singh N. Translation of open reading frame in kinetoplast DNA minicircles of clinical isolates of L. donovani. Parasitol Res. 2007 Mar; 100(4):893-7. PMID: 17047999.
      View in: PubMed
    27. Singh N. Drug resistance mechanisms in clinical isolates of Leishmania donovani. Indian J Med Res. 2006 Mar; 123(3):411-22. PMID: 16778320.
      View in: PubMed
    28. Kothari H, Kumar P, Singh N. Prokaryotic expression, purification, and polyclonal antibody production against a novel drug resistance gene of Leishmania donovani clinical isolate. Protein Expr Purif. 2006 Jan; 45(1):15-21. PMID: 16289919.
      View in: PubMed
    29. Dube A, Singh N, Sundar S, Singh N. Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res. 2005 Jun; 96(4):216-23. PMID: 15868188.
      View in: PubMed
    30. Kumar P, Kothari H, Singh N. Overexpression in Escherichia coli and purification of pteridine reductase (PTR1) from a clinical isolate of Leishmania donovani. Protein Expr Purif. 2004 Dec; 38(2):228-36. PMID: 15555938.
      View in: PubMed
    31. Singh N, Dube A. Short report: fluorescent Leishmania: application to anti-leishmanial drug testing. Am J Trop Med Hyg. 2004 Oct; 71(4):400-2. PMID: 15516633.
      View in: PubMed
    32. Singh N, Singh RT, Sundar S. Novel mechanism of drug resistance in kala azar field isolates. J Infect Dis. 2003 Aug 15; 188(4):600-7. PMID: 12898450.
      View in: PubMed
    33. Singh N, Singh RT, Sundar S. Identification of a gene linked to drug resistance in field isolates of Leishmania donovani. Ann Trop Med Parasitol. 2002 Dec; 96(8):839-41. PMID: 12625940.
      View in: PubMed
    34. Bhardwaj D, Hora B, Singh N, Puri SK, Lalitha P, Rupa P, Chauhan VS. Immunogenicity and protective efficacy of three DNA vaccines encoding pre-erythrocytic- and erythrocytic-stage antigens of Plasmodium cynomolgi in rhesus monkeys. FEMS Immunol Med Microbiol. 2002 Sep 06; 34(1):33-43. PMID: 12208604.
      View in: PubMed
    Singh's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description